Skip to main content

eVestment's Top Hedge Funds In November 2019

The penultimate peek into eVestment's institutional investor and consultant clicking activity of 2019 is out, and Canyon Capital's Value Realization Master Fund was the most viewed product on eVestment's platform in November. The remaining nine of the top ten are all new entries this month compared to last month, with Russell Investment's RITC Commodities Fund taking second place and Graham Capital Management's Quant Macro Portfolio coming in third.


At the firm level, top ten mainstay Bridgewater Associates took the top spot, with its Optimal Portfolio Fund the firm's most viewed product last month. AQR came in second, with its Style Premia product the most viewed of AQR's various offerings, and Corbin Capital Partners took the bronze, with its Opportunity Fund getting the most clicks for Corbin.


November's largest Rising Product - the product with the largest increase in views vs. the 6 month moving average - was Russell Investment's RITC Commodities Fund. Bridgewater's Optimal Portfolio Fund was second and Corbin Capital's Opportunity Fund third.

Image removed.

The top Rising firms in November saw Corbin at number 1, Bridgewater at 2 and Russell Investments in third place. At the strategy level, Fundamental Long/Short Equity was the strategy with the most viewed for the 11th successive month, and Macro-Multi-Strat was the strategy with the biggest increase over its 6 month moving average.

We'll be back in January with a look at both the December 2019 and the full year stats from the folks at eVestment so be sure to check back in mid-January for that update.

Content role

© The Sortino Group Ltd

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency or other Reprographic Rights Organisation, without the written permission of the publisher. For more information about reprints from AlphaWeek, click here.